Indication
For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or Janus kinase (JAK) inhibitor.
Medicine details
- Medicine name:
- guselkumab (Tremfya)
- SMC ID:
- SMC2848
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Publication due date:
- 10 November 2025